Reyataz boosted regimen
Ordinarily, treatment of HIV-1 with Reyataz (atazanavir; Bristol Myers Squibb) is boosted by co-administration with ritonavir. However, the summary of product characteristics has been updated to reflect that, under certain circumstances, ritonavir does not need to be co-administered, for example in patients with hepatic impairment.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200039
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com